Cumberland Pharmaceuticals Reports 12% YTD Revenue Growth, Adds Talicia to Commercial Portfolio

Cumberland Pharmaceuticals reported $8.3 million in Q3 net revenues, a 12% YoY increase in year-to-date revenues to $30.8 million, and ended Q3 with $66 million in total assets and $26 million in shareholders' equity. The company recently added Talicia to its commercial portfolio and launched Vibativ in Saudi Arabia, marking progress in its mission to provide unique products that improve patient care.